E3200

NCT00029549 📎

Regimen

Experimental
Bevacizumab 10 mg/kg Q2W + FOLFOX4
Control
FOLFOX4 alone; bevacizumab monotherapy as third arm

Population

Metastatic CRC, 2L, bevacizumab-naive, after prior irinotecan-containing chemotherapy.

Key finding

2L mCRC (post-fluoropyrimidine+irinotecan): FOLFOX4+bev vs FOLFOX4: mOS 12.9 vs 10.8 mo (HR 0.75, p=0.0011); mPFS 7.3 vs 4.7 mo (HR 0.61, p<0.0001); ORR 22.7% vs 8.6% (p<0.0001); bev monotherapy: mOS 10.2 mo — minimal activity

Source: PMID 17442997

Timeline

    Guideline citations

    • NCCN Colon (p.147)